

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
10/714,211	11/14/2003	Joseph Edward Zahner	NR 03-001	5750		
32809 Joseph E. Zahn	7590 01/16/2008 er		EXAMINER  NOBLE, MARCIA STEPHENS			EXAMINER
4 Meredith Dri	ve					
Sparta, NJ 078	/1		ART UNIT	PAPER NUMBER		
•			1632			
•				9		
			MAIL DATE	DELIVERY MODE		
		•	01/16/2008	PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/714,211	ZAHNER, JOSEPH EDWARD		
Examiner	Art Unit		
Marcia S. Noble	1632		

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --THE REPLY FILED 20 December 2007 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. 1. Me The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods: a) The period for reply expires <u>3</u> months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL 2. The Notice of Appeal was filed on \_\_\_\_\_. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a). **AMENDMENTS** 3. X The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below): (b) They raise the issue of new matter (see NOTE below); (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or (d) They present additional claims without canceling a corresponding number of finally rejected claims. NOTE: See Continuation Sheet. (See 37 CFR 1.116 and 41.33(a)). 4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324). 5. Applicant's reply has overcome the following rejection(s): \_\_\_\_\_. 6. Newly proposed or amended claim(s) \_\_\_\_\_ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).

Claim(s) rejected: 1-12.
Claim(s) withdrawn from consideration: _
AFFIDAVIT OR OTHER EVIDENCE

Claim(s) allowed: Claim(s) objected to:

8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).

7. 🛛 For purposes of appeal, the proposed amendment(s): a) 🖾 will not be entered, or b) 🗌 will be entered and an explanation of

9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).

10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.

REQUEST FOR RECONSIDERATION/OTHER

The status of the claim(s) is (or will be) as follows:

11. 🖂 The request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.

	2.		Note the attached	Information	Disclosure	Statement(s).	(PTO/SB/08)	Paper No(s).	
--	----	--	-------------------	-------------	------------	---------------	-------------	--------------	--

how the new or amended claims would be rejected is provided below or appended.

SUPERVISORY PATENT EXAMINER

TECHNOLOGY CENTER 1600

13. Other: \_\_\_\_\_.

## Continuation Sheet (PTO-303)

Continuation of 3. NOTE: The amendment to claim 1 recites, "affecting a change in gene expression of a keratinocyte". The amendment to the claims also remove "reprogramming a keratinocyte" and "reprogrammed cell". The addition of the phrase "affecting a change in gene expression of a keratinocyte" and the removal of recitations encompassing reprogramming broaden the scope of the instant claims and therefore the amendment would require new considerations and search. Also "affecting a change in gene expression" broadens the scope to causing any change in gene expression. The specification does not provide implicit or explicit support for any other changes in gene expression other than changes that result from exposure to methylation and deacetylation agents that may be involved in reprogramming a cell. Therefore, this recitation along with the removal of reprogramming language introduces issues of new matter. Therefore, because the amendments introduce new issues of consideration and search and introduce new matter, the amendments will not be entered.

Continuation of 11. does NOT place the application in condition for allowance because: 112 2nd Paragraph

Claims 1-12 stand rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

Applicant traverses this rejection on the grounds that the amendment to the claims now limit the scope of the invention to the working examples found in paragraphs [0096], [0163], and [164]. This argument is not found persuasive because the disclosure in these paragraphs teach a change in the expression of the telomerase gene and neural specific genes that result from the exposure of keratinocytes to deacetylating and methylating agents. However, the claims encompass affecting any change in any gene expression profile of a keratinocyte, which encompasses many more genes than disclosed in the above paragraphs. However, the specification does not support such broad changes in gene expression profiles and only teaches changes associated with reprogramming a cell, which are also not enabled. Therefore, because Applicant's arguments are not found persuasive and also because the amendments are not being entered, the instant rejection is maintained.